An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Geoffrey Wu
Advertisement
Geoffrey Wu, PhD*, is a regulatory review officer, [email protected].
Articles by Geoffrey Wu
Advertisement
Latest Updated Articles
Advertisement
Advertisement